Abstract
A spinal cord injury leads to disturbances of sensory and motor signals due to the damage to white matter and myelinated fiber tracts. Moreover, the damage to gray matter causes segmental loss of interneurons of dorsal horn and motoneurons and restricts the therapeutic options. Neuroprotective strategies have the potential to improve the neurological outcome of patients. To achieve this, concerns to anesthetics or analgesics as neuroprotective interventions have been accumulating to explore neuroprotection during perioperative period.
This review includes consideration of: 1) basic concepts of the pathophysiological mechanisms following spinal cord injury and 2) anesthetics and analgesics displaying neuroprotective potential. In particular, we review the application of isoflurane as an inhalational neuroprotectant and discuss evidence for the neuroprotection provided by barbiturates. In addition, 3) recent advances in stem cell biology, neural injury and repair, and progress toward the development of neuroprotective and regenerative interventions are the basis for increased optimism.
Keywords: Spinal cord ischemia/injury, anesthetics, analgesic, neuroprotection, isoflurane, barbiturates, hypothermia, preconditioning, cellbased therapy/ transplantation.
Current Pharmaceutical Design
Title:Spinal Cord Ischemia/Injury
Volume: 20 Issue: 36
Author(s): Ishikawa T., Suzuki H., Ishikawa K., Yasuda S., Matsui T., Yamamoto M., Kakeda T., Yamamoto S., Owada Y. and Yaksh T.L.
Affiliation:
Keywords: Spinal cord ischemia/injury, anesthetics, analgesic, neuroprotection, isoflurane, barbiturates, hypothermia, preconditioning, cellbased therapy/ transplantation.
Abstract: A spinal cord injury leads to disturbances of sensory and motor signals due to the damage to white matter and myelinated fiber tracts. Moreover, the damage to gray matter causes segmental loss of interneurons of dorsal horn and motoneurons and restricts the therapeutic options. Neuroprotective strategies have the potential to improve the neurological outcome of patients. To achieve this, concerns to anesthetics or analgesics as neuroprotective interventions have been accumulating to explore neuroprotection during perioperative period.
This review includes consideration of: 1) basic concepts of the pathophysiological mechanisms following spinal cord injury and 2) anesthetics and analgesics displaying neuroprotective potential. In particular, we review the application of isoflurane as an inhalational neuroprotectant and discuss evidence for the neuroprotection provided by barbiturates. In addition, 3) recent advances in stem cell biology, neural injury and repair, and progress toward the development of neuroprotective and regenerative interventions are the basis for increased optimism.
Export Options
About this article
Cite this article as:
T. Ishikawa, H. Suzuki, K. Ishikawa, S. Yasuda, T. Matsui, M. Yamamoto, T. Kakeda, S. Yamamoto, Y. Owada and T.L. Yaksh, Spinal Cord Ischemia/Injury, Current Pharmaceutical Design 2014; 20 (36) . https://dx.doi.org/10.2174/1381612820666140204113252
DOI https://dx.doi.org/10.2174/1381612820666140204113252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry MiR-34a Inhibits Spinal Cord Injury and Blocks Spinal Cord Neuron Apoptosis by Activating Phatidylinositol 3-kinase (PI3K)/AKT Pathway Through Targeting CD47
Current Neurovascular Research Ischemic Neuronal Damage
Current Pharmaceutical Design Pro-Drugs for Indirect Cannabinoids as Therapeutic Agents
Current Drug Delivery Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants
Central Nervous System Agents in Medicinal Chemistry Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
Current Drug Delivery Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain
Current Topics in Medicinal Chemistry Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Adult Stem Cell Transplants for Spinal Cord Injury Repair: Current State in Preclinical Research
Current Stem Cell Research & Therapy An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Gelatin-Siloxane Hybrid Scaffolds with Vascular Endothelial Growth Factor Induces Brain Tissue Regeneration
Current Neurovascular Research Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Treating Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Neurotoxicity of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Kappa Receptor Bivalent Ligands
Current Topics in Medicinal Chemistry Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Current Drug Targets Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry